Works by Tong, Hongyan


Results: 106
    1
    2
    3
    4
    5
    6
    7

    Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.

    Published in:
    American Journal of Hematology, 2024, v. 99, n. 9, p. 1768, doi. 10.1002/ajh.27412
    By:
    • Röth, Alexander;
    • He, Guangsheng;
    • Tong, Hongyan;
    • Lin, Zenghua;
    • Wang, Xiaoqin;
    • Chai‐Adisaksopha, Chatree;
    • Lee, Je‐Hwan;
    • Brodsky, Andres;
    • Hantaweepant, Chattree;
    • Dumagay, Teresita E.;
    • Demichelis‐Gómez, Roberta;
    • Rojnuckarin, Ponlapat;
    • Sun, Jing;
    • Höglund, Martin;
    • Jang, Jun Ho;
    • Gaya, Anna;
    • Silva, Fernando;
    • Obara, Naoshi;
    • Kelly, Richard J.;
    • Beveridge, Leigh
    Publication type:
    Article
    8
    9
    10

    Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single‐arm, open‐label, phase 2, multicenter study.

    Published in:
    American Journal of Hematology, 2023, v. 98, n. 10, p. 1579, doi. 10.1002/ajh.27031
    By:
    • Zhang, Yi;
    • Zhang, Qike;
    • Liu, Qingchi;
    • Dang, Huibing;
    • Gao, Sujun;
    • Wang, Wei;
    • Zhou, Hu;
    • Chen, Yuqing;
    • Ma, Liangming;
    • Wang, Jishi;
    • Yang, Haiping;
    • Lu, Binhua;
    • Yin, Hewen;
    • Wu, Liqing;
    • Suo, Shanshan;
    • Zhao, Qingwei;
    • Tong, Hongyan;
    • Jin, Jie
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29

    The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative/hepatitis B core antibody positive patients with diffuse large B-cell lymphoma receiving rituximab-based chemotherapy.

    Published in:
    Leukemia & Lymphoma, 2015, v. 56, n. 4, p. 1027, doi. 10.3109/10428194.2014.947606
    By:
    • Lu, Shasha;
    • Xu, Yu;
    • Mu, Qitian;
    • Cao, Lihong;
    • Chen, Jian;
    • Zhu, Zhijuan;
    • Lou, Yinjun;
    • Meng, Haitao;
    • Qian, Wenbin;
    • Tong, Hongyan;
    • Mai, Wenyuan;
    • Huang, Jian;
    • Yu, Wenjuan;
    • Zhao, Xiaoying;
    • Jin, Jie
    Publication type:
    Article
    30
    31
    32

    Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria.

    Published in:
    British Journal of Clinical Pharmacology, 2025, v. 91, n. 5, p. 1479, doi. 10.1111/bcp.16394
    By:
    • Cosson, Valérie;
    • Fu, Rong;
    • Kulasekararaj, Austin;
    • Nishimura, Jun‐Ichi;
    • Panse, Jens;
    • Röth, Alexander;
    • Scheinberg, Phillip;
    • Tong, Hongyan;
    • Yoon, Sung‐Soo;
    • Beveridge, Leigh;
    • Gotanda, Keisuke;
    • Jaminion, Félix;
    • Henrich, Andrea;
    • Lundberg, Pontus;
    • Shi, Dayu;
    • Sreckovic, Sasha;
    • Zhang, Yuchen;
    • Zhang, Zilu;
    • Benkali, Khaled;
    • Buatois, Simon
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39

    Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher‐risk myelodysplastic syndromes: a prospective multicenter single‐arm trial.

    Published in:
    Hematological Oncology, 2020, v. 38, n. 4, p. 531, doi. 10.1002/hon.2755
    By:
    • Zhou, Xinping;
    • Mei, Chen;
    • Zhang, Jin;
    • Lu, Ying;
    • Lan, Jianping;
    • Lin, Shengyun;
    • Zhang, Yuefeng;
    • Kuang, Yuemin;
    • Ren, Yanling;
    • Ma, Liya;
    • Wei, Juying;
    • Ye, Li;
    • Xu, Weilai;
    • Li, Kongfei;
    • Lu, Chenxi;
    • Jin, Jie;
    • Tong, Hongyan
    Publication type:
    Article
    40
    41

    Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 4, p. 845, doi. 10.1007/s00432-021-03905-y
    By:
    • Jiang, Lingxu;
    • Ye, Li;
    • Ma, Liya;
    • Ren, Yanling;
    • Zhou, Xinping;
    • Mei, Chen;
    • Xu, Gaixiang;
    • Yang, Haiyang;
    • Lu, Chenxi;
    • Luo, Yingwan;
    • Zhu, Shuanghong;
    • Wang, Lu;
    • Shen, Chuying;
    • Yang, Wenli;
    • Zhang, Qi;
    • Wang, Yuxia;
    • Lang, Wei;
    • Han, Yueyuan;
    • Jin, Jie;
    • Tong, Hongyan
    Publication type:
    Article
    42

    Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2018, v. 144, n. 6, p. 1037, doi. 10.1007/s00432-018-2627-3
    By:
    • Lin, Peipei;
    • Luo, Yingwan;
    • Zhu, Shuanghong;
    • Maggio, Dominic;
    • Yang, Haiyang;
    • Hu, Chao;
    • Wang, Jinghan;
    • Zhang, Hua;
    • Ren, Yanling;
    • Zhou, Xinping;
    • Mei, Chen;
    • Ma, Liya;
    • Xu, Weilai;
    • Ye, Li;
    • Zhuang, Zhengping;
    • Jin, Jie;
    • Tong, Hongyan
    Publication type:
    Article
    43
    44
    45
    46
    47
    48
    49
    50